Pancreasin Inhibitors
Pancreasin inhibitors are chemical compounds that specifically target and inhibit the activity of pancreasin, a serine protease enzyme primarily expressed in the pancreas. As a member of the serine protease family, pancreasin plays a key role in the breakdown of proteins by cleaving peptide bonds, particularly within the digestive system. It is involved in the hydrolysis of dietary proteins into smaller peptides and amino acids, which can then be absorbed and utilized by the body. By inhibiting pancreasin, these compounds prevent the enzyme from carrying out its proteolytic function, affecting protein digestion and potentially altering the balance of digestive processes.
Researchers use pancreasin inhibitors to study the enzymatic mechanisms of protein degradation in the digestive system, gaining insights into how specific proteases like pancreasin contribute to the overall efficiency of protein digestion. Inhibition of pancreasin allows for the investigation of how reduced protease activity impacts the breakdown of dietary proteins and the subsequent absorption of nutrients. These inhibitors are valuable tools for understanding the regulation of proteolytic enzymes and their specific roles in digestive physiology. By exploring the effects of pancreasin inhibition, scientists can also study broader aspects of serine protease function in various tissues and biological contexts, further illuminating the complex interactions involved in proteolysis. Pancreasin inhibitors thus provide critical insights into enzyme specificity, protease regulation, and the role of serine proteases in maintaining proper digestive function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide may downregulate Pancreasin by repressing the activity of specific transcription factors essential for the initiation of the PRSS27 gene transcription, resulting in decreased mRNA production. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D can bind to DNA and obstruct RNA polymerase movement, leading to a halt in the transcriptional process and subsequent reduction in Pancreasin synthesis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin may decrease Pancreasin synthesis by inhibiting mTOR pathway-induced protein translation, thereby reducing the overall protein production, including that of Pancreasin. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide could inhibit the elongation step of mRNA translation on ribosomes, leading to a reduction in Pancreasin production at the post-transcriptional level. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may promote the demethylation of the PRSS27 gene promoter, which could lead to the suppression of Pancreasin by altering the transcriptional accessibility of its gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A might downregulate Pancreasin expression by inhibiting histone deacetylases, which would result in a less condensed chromatin structure and suppression of gene activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 could decrease Pancreasin expression by specifically inhibiting the MAPK/ERK pathway, which may play a role in the transcriptional regulation of the PRSS27 gene. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 may lead to a decrease in Pancreasin levels by inhibiting the PI3K pathway, which is crucial for the activation of transcription factors that govern the expression of the PRSS27 gene. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib could indirectly reduce Pancreasin expression by inhibiting proteasomal degradation, leading to cellular stress and potential downregulation of various gene expressions, including PRSS27. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin may lead to the downregulation of Pancreasin by stabilizing a complex between DNA and topoisomerase I, causing DNA damage and potentially inhibiting PRSS27 gene transcription. | ||||||